Pulmatrix Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
96.00
15,571.00
18,902.00
4,182.00
3,550.00
2,563
Total Accounts Receivable
-
-
481.00
206.00
1.00
-
Other Current Assets
4.00
3.00
1,079.00
264.00
668.00
689
Total Current Assets
100.00
15,574.00
20,462.00
4,652.00
4,219.00
3,252
Net Property, Plant & Equipment
4.00
2.00
685.00
786.00
614.00
394
Total Investments and Advances
-
-
250.00
204.00
204.00
204
Intangible Assets
-
-
23,476.00
10,914.00
10,914.00
10,845
Other Assets
44.00
-
-
107.00
27.00
28
Total Assets
148.00
15,576.00
44,873.00
16,663.00
15,978.00
14,723
ST Debt & Current Portion LT Debt
-
-
1,029.00
2,586.00
3,221.00
Accounts Payable
-
-
1,090.00
747.00
457.00
Other Current Liabilities
101.00
947.00
1,486.00
1,317.00
2,162.00
Total Current Liabilities
101.00
947.00
3,605.00
4,650.00
5,840.00
Long-Term Debt
-
-
5,692.00
3,217.00
-
Deferred Taxes
-
-
2,959.00
-
-
Other Liabilities
-
-
11.00
35.00
1.00
Total Liabilities
101.00
947.00
12,267.00
7,902.00
5,841.00
Common Equity (Total)
47.00
14,629.00
32,606.00
8,761.00
10,137.00
Total Shareholders' Equity
47.00
14,629.00
32,606.00
8,761.00
10,137.00
Total Equity
47.00
14,629.00
32,606.00
8,761.00
10,137.00
Liabilities & Shareholders' Equity
148.00
15,576.00
44,873.00
16,663.00
15,978.00

About Pulmatrix

View Profile
Address
99 Hayden Avenue
Lexington Massachusetts 02421
United States
Employees -
Website http://www.pulmatrix.com
Updated 07/08/2019
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products. The company focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.